{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T10:25:15Z","timestamp":1791109515572,"version":"4.1.0"},"reference-count":56,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2007,2,1]],"date-time":"2007-02-01T00:00:00Z","timestamp":1170288000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2007,2]]},"DOI":"10.1002\/jps.20780","type":"journal-article","created":{"date-parts":[[2006,10,18]],"date-time":"2006-10-18T22:18:40Z","timestamp":1161209920000},"page":"235-248","source":"Crossref","is-referenced-by-count":182,"title":["Lipid Formulation Strategies for Enhancing Intestinal Transport and Absorption of P-Glycoprotein (P-gp) Substrate Drugs: In vitro\/In vivo Case Studies"],"prefix":"10.1016","volume":"96","author":[{"given":"Panayiotis P.","family":"Constantinides","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kishor M.","family":"Wasan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1002\/jps.20780_bb0010","first-page":"115","article-title":"Recent progress in P-glycoprotein research","volume":"14","author":"Ueda","year":"1999","journal-title":"Anticancer Drug Design"},{"key":"10.1002\/jps.20780_bb0015","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S0169-409X(97)00497-3","article-title":"Intestinal secretion of drugs. The role of P-glycoprotein and related drug efflux systems in limiting oral drug absorption","volume":"25","author":"Hunter","year":"1997","journal-title":"Adv Drug Del Rev"},{"key":"10.1002\/jps.20780_bb0020","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S1043-6618(03)00158-0","article-title":"P-glycoprotein inhibitors and their screening: A perspective from bioavailability enhancement","volume":"48","author":"Varma","year":"2003","journal-title":"Pharmacol Res"},{"key":"10.1002\/jps.20780_bb0025","doi-asserted-by":"crossref","first-page":"6887","DOI":"10.1021\/bi990064q","article-title":"The membrane lipid environment modulates drug interactions with the P-glycoprotein multidrug transporter","volume":"38","author":"Romsicki","year":"1999","journal-title":"Biochemistry"},{"key":"10.1002\/jps.20780_bb0030","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/0968-0004(92)90419-A","article-title":"Is the multidrug transporter a flippase?","volume":"17","author":"Higgins","year":"1992","journal-title":"Trends Biochem Sci"},{"key":"10.1002\/jps.20780_bb0035","doi-asserted-by":"crossref","first-page":"12897","DOI":"10.1074\/jbc.271.22.12897","article-title":"The role of passive transbilayer drug movement in multidrug resistance and its modulation","volume":"271","author":"Eytan","year":"1996","journal-title":"J Biol Chem"},{"key":"10.1002\/jps.20780_bb0040","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1007\/s002280100369","article-title":"In vitro prediction of gastrointestinal absorption and bioavailability: An experts' meeting report","volume":"57","author":"Pelkonen","year":"2001","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1002\/jps.20780_bb0045","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S0169-409X(02)00175-8","article-title":"Considerations in the design and development of transport inhibitors as adjuncts to drug therapy","volume":"55","author":"Dantzig","year":"2003","journal-title":"Adv Drug Del Rev"},{"key":"10.1002\/jps.20780_bb0050","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0928-0987(00)00177-9","article-title":"Structure-activity relationship of P-glycoprotein substrates and modifiers","volume":"12","author":"Seelig","year":"2000","journal-title":"Eur J Pharm Sci"},{"key":"10.1002\/jps.20780_bb0055","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.ijpharm.2004.03.001","article-title":"Impact of excipients on the absorption of P-glycoprotein substrates in vitro and in vivo","volume":"278","author":"Cornaire","year":"2004","journal-title":"Int J Pharm"},{"key":"10.1002\/jps.20780_bb0060","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1023\/B:PHAM.0000036925.45002.a2","article-title":"Evidence for modulation of P-glycoprotein-mediated efflux by methoxypolyethylene glycol-block-polycaprolactone amphiphilic diblock copolymers","volume":"21","author":"Zastre","year":"2004","journal-title":"Pharma Res"},{"key":"10.1002\/jps.20780_bb0065","doi-asserted-by":"crossref","first-page":"24995","DOI":"10.1016\/S0021-9258(19)73996-9","article-title":"Modulation of P-glycoprotein-mediated drug transport by alterations in lipid fluidity of rat liver canalicular membrane vesicles","volume":"267","author":"Sinicrope","year":"1992","journal-title":"J Biol Chem"},{"key":"10.1002\/jps.20780_bb0070","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1046\/j.1432-1327.1999.00037.x","article-title":"Membrane fluidization by ether, other anesthetics, and certain agents abolishes P-glycoprotein ATPase activity and modulates efflux from multi-drug\u2014resistant cells","volume":"259","author":"Regev","year":"1999","journal-title":"Eur J Biochem"},{"key":"10.1002\/jps.20780_bb0075","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1002\/jps.10395","article-title":"The role of surfactants in the reversal of active transport mediated by multidrug resistance proteins","volume":"92","author":"Bogman","year":"2003","journal-title":"J Pharm Sci"},{"key":"10.1002\/jps.20780_bb0080","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1002\/ijc.2910620413","article-title":"Comparison of solutol HS15, cremophor EL and novel ethoxylated fatty acid surfactants as multidrug resistance modification agents","volume":"62","author":"Buckingham","year":"1995","journal-title":"Int J Cancer"},{"key":"10.1002\/jps.20780_bb0085","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1002\/jps.10176","article-title":"A comparison of commonly used polyethoxylated pharmaceutical excipients on their ability to inhibit P-glycoprotein activity in vitro","volume":"91","author":"Hugger","year":"2002","journal-title":"J Pharm Sci"},{"key":"10.1002\/jps.20780_bb0090","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S0168-3659(03)00163-9","article-title":"Relationships between the hydrophilic-lipophilic balance values of pharmaceutical excipients and their multidrug resistance modulating effect in Caco-2 cells and rat intestines","volume":"90","author":"Lo","year":"2003","journal-title":"J Control Rel"},{"key":"10.1002\/jps.20780_bb0095","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1002\/jps.1127","article-title":"Effect of common excipients on Caco-2 transport of low-permeability drugs","volume":"90","author":"Rege","year":"2001","journal-title":"J Pharm Sci"},{"key":"10.1002\/jps.20780_bb0100","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/S0928-0987(02)00055-6","article-title":"Effects of non-ionic surfactants on membrane transporters in Caco-2 cell monolayers","volume":"16","author":"Rege","year":"2002","journal-title":"Eur J Pharm Sci"},{"key":"10.1002\/jps.20780_bb0105","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1002\/jps.2600810908","article-title":"Epithelial transport of drugs in cell culture. VII: Effects of pharmaceutical surfactant excipients and bile acids on transepithelial permeability in monolayers of human intestinal epithelial (Caco-2 cells)","volume":"81","author":"Anderberg","year":"1992","journal-title":"J Pharm Sci"},{"key":"10.1002\/jps.20780_bb0110","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S0304-3835(99)00355-9","article-title":"Non-ionic detergent Tween 80 modulates VP-16 resistance in classical multidrug resistant K562 cells via enhancement of VP-16 influx","volume":"149","author":"Yamazaki","year":"2000","journal-title":"Cancer Lett"},{"key":"10.1002\/jps.20780_bb0115","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/S0006-2952(99)00377-9","article-title":"Effects of sodium deoxycholate and sodium caprate on the transport of epirubicin in human intestinal epithelial Caco-2 cell layers and everted gut sacs of the rats","volume":"59","author":"Lo","year":"2000","journal-title":"Biochem Pharmacol"},{"key":"10.1002\/jps.20780_bb0120","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1023\/A:1016268311867","article-title":"Lipid microemulsions for improving drug dissolution and oral absorption: Physical and biopharmaceutical aspects","volume":"12","author":"Constantinides","year":"1995","journal-title":"Pharm Res"},{"key":"10.1002\/jps.20780_bb0125","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1023\/A:1016212804288","article-title":"A theoretical basis for a biopharmaceutic drug classification: The correlation of in vitro drug product dissolution and in vivo bioavailability","volume":"12","author":"Amidon","year":"1995","journal-title":"Pharm Res"},{"key":"10.1002\/jps.20780_bb0130","unstructured":"Fast DJ,Patil RT,Bosman KS,Loy LP,Constantinides PP.2002.Enhancement of paclitaxel transport and intestinal absorption using lipid polymer emulsions (LPE\u2122) incorporating P-glycoprotein inhibitors. International Symposium on Tumor Targeted Delivery Systems, Bethesda, MD."},{"key":"10.1002\/jps.20780_bb0135","unstructured":"Fast DJ,Patil RT,Bosman KS,Constantinides PP.2002.Lipid polymer emulsions (LPE\u2122) incorporating P-glycoprotein inhibitors enhance the intestinal absorption of paclitaxel. Annual Meeting of the American Association of Pharmaceutical Scientists, Toronto, Canada."},{"key":"10.1002\/jps.20780_bb0140","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1097\/00001813-199607000-00012","article-title":"Ranking of P-glycoprotein substrates and inhibitors by a calcein-AM fluorometry screening assay","volume":"7","author":"Tiberghien","year":"1996","journal-title":"Anticancer Drug"},{"key":"10.1002\/jps.20780_bb0145","series-title":"Epithelial cell culture: A practical approach","article-title":"1. Studying transport processes in absorptive epithelia","author":"Artursson","year":"1996"},{"key":"10.1002\/jps.20780_bb0150","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1023\/A:1016060729594","article-title":"An integrated method to determine epithelial transport and bioactivity of oral drug candidates in vitro","volume":"13","author":"Rubas","year":"1996","journal-title":"Pharm Res"},{"key":"10.1002\/jps.20780_bb0155","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.ejps.2005.04.003","article-title":"Enhanced oral paclitaxel absorption with vitamin E-TPGS: Effect of solubility and permeability in vitro, in situ and in vivo","volume":"25","author":"Varma","year":"2005","journal-title":"Eur J Pharm Sci"},{"key":"10.1002\/jps.20780_bb0160","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1023\/A:1018939006780","article-title":"Vitamin E-TPGS increases absorption flux of an HIV Protease Inhibitor by enhancing its solubility and permeability","volume":"16","author":"Yu","year":"1999","journal-title":"Pharm Res"},{"key":"10.1002\/jps.20780_bb0165","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.jconrel.2005.11.005","article-title":"Influence of vitamin E TPGS poly(ethylene glycol) chain length on apical efflux transporters in Caco-2 cell monolayers","volume":"111","author":"Collnot","year":"2006","journal-title":"Control Rel"},{"key":"10.1002\/jps.20780_bb0170","doi-asserted-by":"crossref","first-page":"E40","DOI":"10.1208\/ps040440","article-title":"An vitro examination of the impact of polyethylene glycol 400, Pluronic P85, and vitamin-E D-alpha-tocopheryl-polyethylene glycol 1000-succinate on P-glycoprotein efflux and enterocyte-based metabolism in excised rat intestine","volume":"4","author":"Johnson","year":"2002","journal-title":"AAPS Pharm Sci"},{"key":"10.1002\/jps.20780_bb0175","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1002\/jps.20127","article-title":"Preclinical and clinical evaluation of solution and soft gelatin capsule formulations for BCS class 3 compound with atypical physicochemical properties","volume":"93","author":"Ramsay-Olocco","year":"2004","journal-title":"J Pharm Sci"},{"key":"10.1002\/jps.20780_bb0180","doi-asserted-by":"crossref","first-page":"3339","DOI":"10.1128\/AAC.47.10.3339-3342.2003","article-title":"Effect of various lipid-based oral formulations on plasma and tissue concentrations and renal toxicity of amphotericin B within male rats","volume":"47","author":"Risovic","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1002\/jps.20780_bb0185","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1081\/DDC-120039793","article-title":"Potential mechanisms by which peceol increases the gastrointestinal absorption of amphotericin B","volume":"30","author":"Risovic","year":"2004","journal-title":"Drug Dev Ind Pharm"},{"key":"10.1002\/jps.20780_bb0190","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S0169-409X(96)00490-5","article-title":"Formulation of self-emulsifying drug delivery systems","volume":"25","author":"Pouton","year":"1997","journal-title":"Adv Drug Del Rev"},{"key":"10.1002\/jps.20780_bb0195","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/S0939-6411(00)00089-8","article-title":"Self-dispersing lipid formulations for improving oral absorption of lipophilic drugs","volume":"50","author":"Gershanik","year":"2000","journal-title":"Eur J Pharm Biopharm"},{"key":"10.1002\/jps.20780_bb0200","series-title":"Controlled drug delivery: Designing technologies for the future","first-page":"284","article-title":"Self-emulsifying drug delivery formulations in the 21st century: Challenges and opportunities","author":"Constantinides","year":"2000"},{"key":"10.1002\/jps.20780_bb0205","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s11095-005-9262-9","article-title":"Advances in the use of tocols as drug delivery vehicles","volume":"23","author":"Constantinides","year":"2006","journal-title":"Pharm Res"},{"key":"10.1002\/jps.20780_bb0210","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.ejps.2003.08.005","article-title":"Lipid drug delivery and rational formulation design for lipophilic drugs with low oral bioavailability, applied to Cyclosporine","volume":"20","author":"Odeberg","year":"2003","journal-title":"Eur J Pharm Sci"},{"key":"10.1002\/jps.20780_bb0215","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/0140-6736(91)90349-T","article-title":"Improvement of cyclosporine absorption in children after liver transplantation by means of water-soluble vitamin E","volume":"338","author":"Sokol","year":"1991","journal-title":"Lancet"},{"key":"10.1002\/jps.20780_bb0220","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1002\/j.1875-9114.1996.tb02916.x","article-title":"Enhanced oral cyclosporine absorption with water-soluble vitamin E early after liver transplantation","volume":"16","author":"Pan","year":"1996","journal-title":"Pharmacother"},{"key":"10.1002\/jps.20780_bb0225","first-page":"1875","article-title":"Use of water-soluble liquid vitamin E to enhance cyclosporine absorption in children after liver transplant","volume":"25","author":"Boudreaux","year":"1993","journal-title":"Transplant Proc"},{"key":"10.1002\/jps.20780_bb0230","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/S0009-9236(96)80007-5","article-title":"The effect of water-soluble vitamin E on cyclosporine pharmacokinetics in healthy volunteers","volume":"59","author":"Chang","year":"1996","journal-title":"Clin Pharmacol Ther"},{"key":"10.1002\/jps.20780_bb0235","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1023\/A:1015000503629","article-title":"Inhibition of P-glycoprotein by D-alpha-tocopheryl polyethylene glycol succinate (TPGS)","volume":"16","author":"Dintaman","year":"1999","journal-title":"Pharm Res"},{"key":"10.1002\/jps.20780_bb0240","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1073\/pnas.94.5.2031","article-title":"Limited oral bioavailability and active epithelial excretion of Paclitaxel (Taxol) caused by P-glucoprotein in the intestine","volume":"94","author":"Sparreboom","year":"1997","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1002\/jps.20780_bb0245","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1023\/A:1022286422439","article-title":"Enhanced oral bioavailability of paclitaxel by coadministration of the P-glycoprotein inhibitor KR30031","volume":"20","author":"Woo","year":"2003","journal-title":"Pharm Res"},{"key":"10.1002\/jps.20780_bb0250","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1023\/A:1010635000879","article-title":"Oral delivery of taxanes","volume":"19","author":"Malingre","year":"2001","journal-title":"Invest New Drugs"},{"key":"10.1002\/jps.20780_bb0255","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1023\/A:1010618632738","article-title":"Role of formulation vehicles in taxane pharmacology","volume":"19","author":"Van Zuylen","year":"2001","journal-title":"Invest New Drugs"},{"key":"10.1002\/jps.20780_bb0260","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/S0928-0987(00)00153-6","article-title":"Modulation of oral bioavailability of anticancer drugs: From mouse to man","volume":"12","author":"Schellens","year":"2000","journal-title":"Eur J Pharm Sci"},{"key":"10.1002\/jps.20780_bb0265","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1023\/B:PHAM.0000016238.44452.f1","article-title":"Enhanced oral absorption of paclitaxel in a novel self-microemulsifying drug delivery system with or without concomitant use of P-glycoprotein inhibitors","volume":"21","author":"Yang","year":"2004","journal-title":"Pharm Res"},{"key":"10.1002\/jps.20780_bb0270","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1002\/jps.10511","article-title":"Development of a supersaturable SEDDS (S-SEDDS) formulation of paclitaxel with improved oral bioavailability","volume":"92","author":"Gao","year":"2003","journal-title":"J Pharm Sci"},{"key":"10.1002\/jps.20780_bb0275","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1038\/bjc.1997.530","article-title":"Enhanced oral bioavailability of paclitaxel in mice treated with the P-glycoprotein blocker SDZ PSC 833","volume":"76","author":"van Asperen","year":"1997","journal-title":"Br J Cancer"},{"key":"10.1002\/jps.20780_bb0280","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1023\/A:1011924314899","article-title":"Active apical secretory efflux of the HIV protease inhibitors saquinavir and ritonavir in Caco-2 cell monolayers","volume":"15","author":"Alsenz","year":"1998","journal-title":"Pharm Res"},{"key":"10.1002\/jps.20780_bb0285","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1023\/B:PHAM.0000016235.32639.23","article-title":"Solubilizing excipients in oral and injectable formulations","volume":"21","author":"Strickley","year":"2004","journal-title":"Pharm Res"}],"container-title":["Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354916321815?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354916321815?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,2,7]],"date-time":"2024-02-07T18:16:28Z","timestamp":1707329788000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022354916321815"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,2]]},"references-count":56,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2007,2]]}},"alternative-id":["S0022354916321815"],"URL":"https:\/\/doi.org\/10.1002\/jps.20780","relation":{},"ISSN":["0022-3549"],"issn-type":[{"value":"0022-3549","type":"print"}],"subject":[],"published":{"date-parts":[[2007,2]]}}}